New data are raising fresh concerns about the diversion of funds under the 340B Drug Pricing Program. More than two-thirds of 340B contract pharmacies were associated with a pharmacy benefit manager (PBM), and more than half were vertically integrated with a PBM or contractually affiliated with a PBM. Those were among the findings of a recent analysis conducted by Avalere for the Community Oncology Alliance (COA).